Inverness Medical Innovations
- Tel: +44 (0) 1234 835000
- Contact this Company »
- Visit Web Site »
Inverness Medical Innovations is a leading provider of innovative diagnostic products for women's health and chronic disease management as well as leading the way in advanced technologies for both the consumer and professional diagnostic markets. We remain committed to advancing healthcare through a continual flow of innovative new products driven by our strategy of investing in R & D and intellectual property. By maintaining our own state-of-the-art manufacturing facilities, we produce high-quality, cutting edge products at the speed of life.
Through our internal R & D programmes, some strategic acquisitions and further planned acquisitions, our portfolio is rapidly growing and evolving. We currently have five key brands: Clearview, TestPack, Binax, Determine and Biostar ensuring that we are at the forefront of the global clinical rapid diagnostics market.
Other products are also available from Inverness Medical Innovations. This includes: Osteomark NTx and ACB (Albumin Cobalt Binding) test for Ischemia Modified Albumin. For further information please contact the following address:
Inverness Medical Innovations
Unipath Limited
Priory Business Park,
Bedford, MK44 3UP,
United Kingdom
Tel: +44 (0) 1234 835000
Fax: +44 (0) 1234 835001
www.clearview.com
www.testpack.com
www.determinetest.com
www.binax.com
www.osteomark.com
www.invernessmedicalpd.com
Drug Awareness
- Rapid Results In Any DOA Scenario New SURESTEP® Drug Screen Tests Launched »
According to the United Nations, some 200 million people, or 5 per cent of the global population, aged 15-64, have used illicit drugs at least once in the last 12 months.
Infection Prevention
- Early Diagnosis For Hospital and Community Acquired Infection – Minutes Not Days! »
Along with MRSA, Clostridium difficile is proving to be a major problem for hospitals worldwide. - Inverness Medical introduces TestPack® Strep A »
Inverness Medical offers the TestPack® Strep A rapid test to tackle the problems caused by delays in diagnosing Streptococcus Group A (Strep A) pharyngitis.
